Nizatidine is a histamine H2-receptor antagonist that inhibits stomach acid production and commonly used in the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD). It was developed by Eli Lilly and is marketed under the brand names Tazac and Axid.
This page contains content from the copyrighted Wikipedia article "Nizatidine"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
